Benzinga
Pfizer-BioNTech’s COVID-19 Vaccine Shows 100% Effectiveness In Long Term Analysis In Adolescents
Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have announced topline results from a longer-term analysis of the safety and efficacy of their COVID-19 Vaccine in individuals 12 through 15 years of age. The updated findings from the Phase 3 trial show that a two-dose series of the Vaccine (30-µg per dose) was 100% effective against COVID-19, measured seven days through over four months after the second dose. Data from almost 2,230 participants showed that 30 cases of COVID-19 were reported